Dana-Farber Cancer Institute
This study aims to evaluate the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML).
This is a phase 2, single-center, interventional study evaluating the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML). The DBP assay is a flow cytometry-based test (functional biomarker) performed on subject biospecimen (bone marrow aspirate) to measure drug-induced apoptotic priming against a pre-set panel of drugs, which can help to identify potentially effective drug combinations. Eligible participants will undergo biomarker screening…
Inclusion Criteria: * Willing to undergo a bone marrow aspirate for biomarker testing. * Participants must have a diagnosis by WHO 2006 of one of the following: * Participants with Relapsed AML must have at least 5% morphologic marrow blasts to be eligible. Extramedullary disease allowed but marrow involvement required. * Participants with Refractory AML are defined as those without a complete remission after two courses (or cycles) of any remission-induction regimen (intensive chemotherapy or less intensive regimen such as hypomethylating agent-venetoclax based treatment or low-dose cyt…
Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.
Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.
Cytarabine will be tested in combination with venetoclax at different dosing strategies. Low-dose cytarabine will be combined with venetoclax in Arm 1. It is also administered as part of the venetoclax-cladribine-based regimen in Arm 6, at low or mid-intensity dosing based on age and fitness, and will be age-adjusted for safety.
Gilteritinib is administered in combination with venetoclax to participants assigned to Treatment 2 based on DBP findings and confirmation of regimen-specific eligibility.
Azacitidine is administered with venetoclax and tagraxofusp in Arm 3 and with venetoclax and revumenib in Arm 5. Dosing of azacitidine is standard at 75 mg/m² daily on Days 1-7.
Tagraxofusp is administered in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.
Decitabine is administered in combination with venetoclax to participants assigned to Treatment 4 based on DBP findings and confirmation of regimen-specific eligibility.
Revumenib is administered orally and in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.
Cladribine is administered with venetoclax and low- or mid-intensity cytarabine in a combination regimen. ladribine is administered at 5 mg/m² daily on Days 1-5 of a 28-day cycle.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.